Liver
Conditions
Interventions
Treatment Group 1:First, neoadjuvant therapy was administered using transcatheter hepatic arterial infusion chemotherapy (HAIC) + sintilimab 200mg + bevacizumab 15mg/kg. After 1-2 cycles of treatment,
Treatment Group 2:Underwent direct surgical resection during initial presentation.
Sponsors
Department of Hepatobiliary Surgery, the First Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have undergone pathological examination or abdominal contrast-enhanced CT/MRI and meet the diagnostic criteria for hepatocellular carcinoma (HCC) as defined by China's 2022 Guidelines for the Diagnosis and Treatment of Primary Liver Cancer; 2. Patients with portal vein tumor thrombus (PVTT), classified as type I or II, and assessed by specialists as having resectable HCC; 3. Previously untreated patients; 4. Liver function classified as Child-Pugh grade A or B, and an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of <2; 5. Patients who have been fully informed about various treatment options, demonstrate good compliance with outpatient follow-up, and have complete follow-up data.
Exclusion criteria
Exclusion criteria: 1. Patients with organic diseases of major organs such as the heart, brain, or kidneys, or those with concurrent malignancies; 2. Patients who have previously undergone treatment for liver cancer; 3. Patients with decompensated liver disease (Child-Pugh grade C); 4. Patients with incomplete or missing clinical data; 5. Patients with poor medication compliance, or women who are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-Free Survival (RFS);Overall Survival (OS); | — |
Countries
China
Contacts
Public ContactLan Xiang
Department of Hepatobiliary Surgery, the First Hospital of Chongqing Medical University
Outcome results
None listed